BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31058185)

  • 1. Relationship between Clinicopathologic Variables in Breast Cancer Overall Survival Using Biogeography-Based Optimization Algorithm.
    Chuang LY; Chen GY; Moi SH; Ou-Yang F; Hou MF; Yang CH
    Biomed Res Int; 2019; 2019():2304128. PubMed ID: 31058185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
    Nguyen F; Peña L; Ibisch C; Loussouarn D; Gama A; Rieder N; Belousov A; Campone M; Abadie J
    Breast Cancer Res Treat; 2018 Feb; 167(3):635-648. PubMed ID: 29086231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of lymph node status in women with breast cancer: A hospital based study from eastern India.
    Chakraborty A; Bose CK; Basak J; Sen AN; Mishra R; Mukhopadhyay A
    Indian J Med Res; 2016 May; 143(Supplement):S45-S51. PubMed ID: 27748277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
    Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
    JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
    Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic features predicting involvement of non- sentinel axillary lymph nodes in Iranian women with breast cancer.
    Moosavi SA; Abdirad A; Omranipour R; Hadji M; Razavi AE; Najafi M
    Asian Pac J Cancer Prev; 2014; 15(17):7049-54. PubMed ID: 25227789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Kim HS; Yoo TK; Park WC; Chae BJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):461-470. PubMed ID: 32020434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.
    Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
    Medicine (Baltimore); 2018 Jul; 97(30):e11647. PubMed ID: 30045313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
    Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
    Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
    Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
    J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
    Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
    Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of breast cancer patients in rural Ethiopia.
    Eber-Schulz P; Tariku W; Reibold C; Addissie A; Wickenhauser C; Fathke C; Hauptmann S; Jemal A; Thomssen C; Kantelhardt EJ
    Breast Cancer Res Treat; 2018 Jul; 170(1):111-118. PubMed ID: 29479644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
    Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
    Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.
    Gosset M; Hamy AS; Mallon P; Delomenie M; Mouttet D; Pierga JY; Lae M; Fourquet A; Rouzier R; Reyal F; Feron JG
    PLoS One; 2016; 11(8):e0159888. PubMed ID: 27494111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.